WilliamDaltonMDPhD

Hematologic Oncology

Founder and Senior Advisor, M2Gen; Emeritus, Senior Member, Moffitt Cancer Center

Dr. Dalton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. William Dalton is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He is also the Founder of M2Gen. He received his medical degree from Indiana University School of Medicine and has been in practice for 37 years. He specializes in hematologic oncology and is experienced in myeloma, health information, and medical informatics. He was a past CEO, and Cancer Center Director of the Moffitt Cancer Center (2002-1012).

University of Arizona College of Medicine-TucsonFellowship, Clinical Pharmacology, 1983 - 1985
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1983 - 1985
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1981 - 1983
Indiana University School of MedicineInternship, Internal Medicine, 1980 - 1981
Indiana University School of MedicineClass of 1980
Indiana University School of MedicinePhD, Toxicology/Pharmacology, 1972 - 1976
University of New MexicoBA, Chemistry/Philosophy, 1967 - 1971

PubMed

10 citations
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.
A.G.M. Mostofa, Allison Distler, Mark B. Meads, Eva Sahakian, John Powers
JCI Insight. 2021-11-18
17 citations
Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC.
Jacob G. Scott, Geoff Sedor, Jessica A. Scarborough, Michael W. Kattan, Jeffrey Peacock
Journal of Thoracic Oncology. 2021-03-01
15 citations
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity.
Nathan D. Seligson, Jeremy L. Warner, William S. Dalton, David Martin, Robert S. Miller
Journal of the American Medical Informatics Association. 2020-11-01

Abstracts/Posters

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker
William S. Dalton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

CEO M2Geninformatics research, cancer genomics2012 - 2022
CEO and Center Director, Moffitt Cancer Center and University of ArizonaMechanisms of drug resistance in cancer with emphasis on the tumor microenvironment and myeloma and breast cancer1985 - 2022